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http://www.biomedcentral.com/1471-2350/15/4RESEARCH ARTICLE Open AccessDifferences in serum SP-D levels between
German and Japanese subjects are associated
with SFTPD gene polymorphisms
Yasushi Horimasu1, Noboru Hattori1*, Nobuhisa Ishikawa1, Sonosuke Tanaka1, Francesco Bonella2,
Shinichiro Ohshimo1, Josune Guzman3, Ulrich Costabel2 and Nobuoki Kohno1Abstract
Background: Surfactant protein A (SP-A) and SP-D are clinically established in Japan as serum biomarkers for
diagnosing interstitial lung diseases (ILDs). Serum SP-D levels are affected by genetic variants. We conducted the
present study to examine whether serum SP-A and/or SP-D levels in healthy subjects (HS) and patients with ILDs
differ between populations with different genetic backgrounds.
Methods: German subjects (n = 303; 138 patients with idiopathic interstitial pneumonias [IIPs] and 165 HS) and
Japanese subjects (n = 369; 94 patients with IIPs and 275 HS) were enrolled. Serum SP-A and SP-D levels were
measured using an enzyme-linked immunosorbent assay, and four single-nucleotide polymorphisms (SNPs) in the
SFTPD gene were genotyped using genomic DNA extracted from blood samples.
Results: In both the German and Japanese cohorts, serum SP-A and SP-D levels were significantly higher in patients
with IIPs than in HS. There were no significant differences in SP-A levels between the German and Japanese cohorts;
however, we found that serum SP-D levels were significantly higher in the German cohort, both in patients with IIPs
and in HS (p < 0.001 and p = 0.005, respectively). Furthermore, the genotype distributions of the four SNPs in the
SFTPD gene (rs721917, rs1998374, rs2243639, and rs3088308) were significantly different between German and
Japanese cohorts (p < 0.001, p < 0.001, p = 0.022, and p < 0.001, respectively), and univariate linear regression
analyses revealed that the genotypes of rs721917, rs1998374, and rs2243639 significantly correlated with serum
SP-D levels (p < 0.001, p < 0.001, and p = 0.011, respectively). Furthermore, multivariate analyses revealed that the
genotypes of these three SNPs correlated independently with serum SP-D levels (p < 0.001, p = 0.001, and p = 0.038,
respectively), whereas ethnicity did not significantly correlate with serum SP-D levels.
Conclusions: In patients with IIPs and HS, serum SP-D, but not SP-A, levels were significantly higher in the German
than in the Japanese cohort, in part, because of the different frequencies of SFTPD gene polymorphisms.
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Idiopathic interstitial pneumonias (IIPs) are a group of
diffuse parenchymal lung diseases characterized by in-
terstitial involvement resulting from various patterns of
inflammation and fibrosis of unknown cause. The preva-
lence of IIPs has been generally reported as 5–20 per
100,000 persons [1-4], with a recommendation that the
diagnosis of IIPs be made according to clinical history,
physical findings, chest radiographs, and/or lung func-
tion tests [5,6]. However, some patients may not complain
of symptoms or present with abnormal chest radiographs
and/or lung function tests, even though they already suffer
from IIPs. Therefore, the availability of diagnostic tools
that can discriminate patients with IIPs from healthy sub-
jects (HS) at an early stage will be undoubtedly useful
in clinical practice. In this regard, serum biomarkers
draw particular interest because they are easy to ob-
tain from patients.
Pulmonary surfactant protein A (SP-A) and SP-D are
water-soluble proteins derived mainly from type II pneu-
mocytes and belong to the collectin subgroup of the
C-type lectin superfamily [7]. Because one of the key
histological feature of the lung affected with interstitial
lung diseases (ILDs) involves injury and/or regeneration
of Type II pneumocytes [8], soluble proteins derived
from Type II pneumocytes, such as SP-A, SP-D, and
Krebs von den Lungen 6 (KL-6), have been studied as
potential biomarkers for ILDs [9-15]. These biomar-
kers can be useful for early detection of ILDs, predicting
disease outcome, and monitoring the clinical course
[16-18]. On the basis of these findings, serum SP-A,
SP-D, and KL-6 have been clinically approved by Japan’s
Health Insurance Program as diagnostic markers for
ILDs in 1999, and more than 2,000,000 samples of
these biomarkers are now examined yearly in Japan. How-
ever, in most countries, assays for these biomarkers are
limited to research and are currently unavailable for
clinical practice.
We recently conducted an international study to mea-
sure the serum levels of KL-6 and analyze the rs4072037
genotypes of Mucin 1 (MUC1) in German and Japanese
cohorts that included patients with ILDs and healthy
subjects. We demonstrated that the cutoff value of KL-6
that discriminated patients with ILDs from HS was
significantly higher in the German than in the Japanese
cohort because of differences in the distribution of
rs4072037 genotypes between them [19]. The correla-
tions between rs4072037 genotypes and serum KL-6
levels have also been demonstrated in a Dutch cohort
[20]. Moreover, serum SP-D levels were found to be cor-
related with genetic polymorphisms of surfactant protein
D (SFTPD) [21-23]. According to the International Hap-
Map project [24], the genotype distributions of some
single-nucleotide polymorphisms (SNPs) in the SFTPDgene differ according to ethnicities. We hypothesized,
therefore, that differences exist in serum SP-D and/or
SP-A levels between different ethnic populations. To test
this hypothesis, we first measured serum SP-A and SP-D
levels and compared them between German and Japanese
cohorts that included patients with IIPs and healthy sub-
jects. Next, we evaluated the correlations between serum
SP-D levels and SFTPD gene polymorphisms in the
German and Japanese cohorts.
Methods
Study subjects
Between February 2007 and December 2011, 138 consecu-
tive German-Caucasian patients with IIPs at Ruhrlandklinik,
University Hospital Essen (Essen, Germany) and 94
Japanese patients with IIPs at Hiroshima University Hos-
pital (Hiroshima, Japan) were enrolled in the present stu-
dy. 165 German-Caucasian and 275 Japanese HS were
recruited from the subjects who visited these hospitals to
undergo health checkup. Diagnoses of IIPs were made ac-
cording to the criteria of the American Thoracic Society
(ATS)/European Respiratory Society (ERS) published in
2002 [5]. We excluded patients with ILDs of known cause,
including drugs, collagen vascular diseases, and hypersen-
sitivity pneumonia. Each HS underwent pulmonary func-
tion tests and chest X-ray studies, and we excluded those
with apparent lung disease such as ILDs or chronic ob-
structive pulmonary disease (COPD). The Ethics Commit-
tees of Ruhrlandklinik (IRB 06-3170) and Hiroshima
University Hospital (IRB 326) approved this study, which
was conducted in accordance with the ethical standards
established by the Helsinki Declaration of 1975. All pa-
tients and healthy volunteers provided written informed
consent to participate in the study and permission to use
their samples.
Lung function values
Physiologic assessment included measurements of tho-
racic gas volume, total lung capacity, forced vital cap-
acity (FVC), forced expiratory volume in one second
(FEV1), and single-breath diffusing capacity of the lung
for carbon monoxide (DLCO) as previously described
[25-28]. The protocol for lung function measurements
conformed to ATS recommendations [29].
Measurement of serum SP-A and SP-D levels
Serum samples were obtained from 234 patients with
IIPs and 440 HS and stored at -80°C. Serum SP-A
and SP-D levels were measured using a sandwich-type
enzyme-linked immunosorbent assay (ELISA) by using
commercially available ELISA kits (SP-A test Kokusai-F
kit, Sysmex Corporation Kobe, Japan; SP-D kit YAMASA
EIA II, Yamasa Corporation Choshi, Japan) as previously
described [28,30].
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We extracted DNA from peripheral whole venous blood
samples by using the phenol-chloroform extraction and
ethanol precipitation methods as previously described
[31]. SNPs only in the SFTPD gene were investigated be-
cause difference in serum levels between German and
Japanese was just observed for SP-D but not for SP-A.
We analyzed HapMap genotyping data [24] by using
chi-square tests and picked up 18 SNPs in the SFTPD
gene that showed significantly different genotype distri-
butions between CEU (Utah residents with ancestry
from northern and western Europe) and JPT (Japanese
in Tokyo, Japan). From these 18 SNPs, we selected four
SNPs (rs721917, rs1998374, rs2243639, and rs3088308;
Figure 1) that have been reported to be associated with
serum SP-D levels [21-23] and/or TaqMan SNP Ge-
notyping Assays are available for. SNP genotyping was
carried out by using TaqMan SNP Genotyping Assay
C 1362980-10, C 12124514-10, C 26726205-10, and
C 26726209-10 (Life Technologies Corp. Carlsbad,
California, USA) and the Applied Biosystems 7500
Fast Real-Time PCR System (Life Technologies Corp.
Carlsbad, California, USA).
Statistical analysis
Data are presented as the mean ± standard error of the
mean (SEM). Data for individual variables for 2 groups
were analyzed using the Mann–Whitney U-test or the
chi-square test. The significance levels for multiple pair-
wise comparisons were set according to Bonferroni’s cor-
rection. Receiver operating characteristic (ROC) curves
were generated to assess the diagnostic abilities of SP-A
and SP-D. Linear regression analyses were conducted to
study the correlations between serum SP-D levels and
each of the four SNPs. If the correlation was statisti-
cally significant, multivariate regression analysis was
performed to determine whether the SNPs in the SFTD
gene independently affect serum SP-D levels even when
adjusted by the covariates as follows: age, ethnicity, and
case-control status. All statistical analyses were per-
formed using SPSS for Windows, version 18.0 (SPSS
Inc. Chicago, USA).11.4kbp
rs721917 rs2243639rs1998374 rs3088308
CRDCCCCS/NTD/C α
Figure 1 Functional features of the SFTPD gene. The thick
horizontal bar represents the intronic region, and the white boxes
represent exons. S, signal peptide; NTD, N-terminal domain; C,
collagen domain; α, α-helical neck region; CRD, carbohydrate
recognition domain.Results
Serum SP-D but not SP-A levels were significantly higher
in the German cohort
The clinical characteristics of 232 patients with IIPs (138
German and 94 Japanese) and 440 HS (165 German and
275 Japanese) are shown in Table 1. Serum SP-A levels
in German HS, German patients with IIPs, Japanese HS,
and Japanese patients with IIPs were 29.7 ± 1.1 ng/ml,
79.4 ± 3.3 ng/ml, 29.4 ± 0.9 ng/ml, and 83.0 ± 6.3 ng/ml,
respectively (Figure 2A). Serum SP-D levels in German
HS, German patients with IIPs, Japanese HS, and Japanese
patients with IIPs were 59.8 ± 2.6 ng/ml, 373.3 ±
20.3 ng/ml, 39.9 ± 1.6 ng/ml, and 323.9 ± 29.8 ng/ml,
respectively (Figure 2B). In both the German and the
Japanese cohort, the serum SP-A and SP-D levels in
patients with IIPs were significantly higher than those in
HS. Further, serum SP-D levels in German HS were sig-
nificantly higher than those in Japanese HS (p < 0.001;
Figure 2B), and serum SP-D levels in German patients
with IIPs were significantly higher than those in Japanese
patients with IIPs (p = 0.005; Figure 2B). In contrast, there
was no significant difference in serum SP-A levels be-
tween the cohorts, within the HS and patients with
IIPs (p = 0.677 for HS and p = 0.326 for patients with
IIPs; Figure 2A).
To evaluate the ability of the serum levels of SP-A and
SP-D to discriminate patients with IIPs from HS, ROC
curves were drawn for each cohort. The areas under the
curves (AUCs) for serum SP-A in the German (AUC =
0.940, 95% confidence interval [CI] = 0.915–0.966;
p < 0.001) and Japanese cohorts (AUC = 0.902, 95%
CI = 0.868–0.936; p < 0.001) were sufficiently high to distin-
guish patients with IIPs from HS (Figure 2C). This was true
for the AUCs for serum SP-D levels in the German (AUC =
0.977, 95% CI = 0.957–0.996; p < 0.001) and Japanese
cohorts as well (AUC = 0.973, 95% CI = 0.952–0.994;
p < 0.001; Figure 2D).
Distributions of SFTPD gene polymorphisms are not
different between patients with IIPs and healthy subjects
DNA was extracted from blood samples from 139 of 303
German (102 patients with IIPs and 37 HS) and 338 of
369 Japanese subjects (63 patients with IIPs and 275
HS). Because collection of whole blood for DNA extrac-
tion was missed or refused, we could not obtain the
genotype data in a part of German patients with IIPs,
German HS, and Japanese patients with IIPs. We com-
pared subject characteristics including serum SP-A and
SP-D levels based on the availability of genotype data
and found that there was no significant difference in
serum SP-A or SP-D levels between the subjects with
and without genotype data in German patients with IIPs,
German HS, or Japanese patients with IIPs (Additional
file 1: Tables S1A and S1B). The genotype distributions
Table 1 Characteristics of study subjects
German Japanese p value
Patients with IIPs
Number of the subjects 138 94
Age (years) 67.4 ± 0.8 68.0 ± 1.0 0.982
Gender (male/female) 88 (63.8%)/50 (36.2%) 64 (68.1%)/30 (31.9%) 0.497
Smoking (Cu/Ex/Non/ND) 14 (10.1%)/54 (39.1%)/ 11 (11.7%)/46 (49.0%)/ 0.297
64 (46.4%)/6 (4.4%) 35 (37.2%)/2 (2.1%)
VC (percent predicted) 66.1 ± 1.6 70.3 ± 2.2 0.163
DLCO (percent predicted) 47.7 ± 1.6 44.8 ± 1.8 0.255
Diagnostic category (IPF/NSIP) 94 (68.1%)/44 (31.9%) 61 (64.9%)/33 (35.1%) 0.609
Healthy subjects
Number of the subjects 165 275
Age (years) 36.5 ± 0.9 49.8 ± 0.4 < 0.001
Gender (male/female) 60 (36.4%)/105 (63.6%) 227 (82.5%)/48 (17.5%) < 0.001
Smoking (Cu/Ex/Non/ND) 41 (24.8%)/20 (12.1%)/ 82 (29.8%)/62 (22.6%)/ 0.026
90 (54.6%)/14 (8.5%) 131 (47.6%)/0 (0.0%)
Data are shown as mean ± SEM.
Statistical significance was tested by Mann–Whitney U-test or Chi-square test.
Cu, Current smoker; Ex, Ex-smoker; Non, Non-smoker; ND, No data; IIPs, Idiopathic interstitial pneumonias; VC, Vital capacity; DLCO, Diffusing capacity of the lung for
carbon monoxide; IPF, Idiopathic pulmonary fibrosis; NSIP, Nonspecific interstitial pneumonia.
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Figure 2 Comparison of serum SP-A and SP-D levels between the cohorts. (A) Serum SP-A and (B) SP-D levels in German and Japanese
cohorts. Receiver operating characteristic (ROC) curves of (C) serum SP-A and (D) SP-D in German (left panel) and Japanese (right panel) cohorts.
The horizontal bars represent the mean values. The significance level was defined α = 0.013 (four comparisons in four groups). ***p < 0.001,
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in German patients with IIPs, German HS, Japanese pa-
tients with IIPs, and Japanese HS (Table 2). As shown in
Table 2, the genotype distributions of the four SNPs did
not differ between patients with IIPs and HS in both
the German and Japanese cohorts. Further, the four
SNPs (rs721917, rs1998374, rs2243639, and rs3088308)
showed significantly different genotype distributions be-
tween the German and Japanese cohorts (p < 0.001, p <
0.001, p = 0.022, and p < 0.001, respectively; Additional
file 2: Table S2).
Serum SP-D levels differ according to SFTPD gene
polymorphisms
Within each German and Japanese cohort, serum SP-D
levels were compared based on the genotypes of each
SNP in the SFTPD gene. Within all genotypes of the
four SNPs, the serum SP-D levels of patients with IIPs
were significantly higher than those of HS in both German
and Japanese cohorts (Figure 3). Furthermore, serum
SP-D levels of Japanese HS were significantly higher in the
rs721917 T/T than in the T/C cohort (p < 0.001) and wereTable 2 Genotype distributions of single nucleotide polymorp
German
rs721917 Total C/C T/C T/T
Patients with IIPs 102 25 47 30
(24.5%) (46.1%) (29.4%)
Healthy subjects 37 9 11 17
(24.3%) (29.7%) (46.0%)
Chi-square test p = 0.140
rs1998374 Total C/C T/C T/T
Patients with IIPs 102 3 18 81
(2.9%) (17.7%) (79.4%)
Healthy subjects 37 0 5 32
(0.0%) (13.5%) (86.5%)
Chi-square test p = 0.464
rs2243639 Total C/C T/C T/T
Patients with IIPs 102 43 45 14
(42.2%) (44.1%) (13.7%)
Healthy subjects 37 13 15 9
(35.1%) (40.6%) (24.3%)
Chi-square test p = 0.324
rs3088308 Total A/A A/T T/T
Patients with IIPs 102 86 16 0
(84.3%) (15.7%) (0.0%)
Healthy subjects 37 32 5 0
(86.5%) (13.5%) (0.0%)
Chi-square test p = 0.752
IIPs, Idiopathic interstitial pneumonias; HWE, Hardy-Weinberg equilibrium.also significantly higher in the T/C than in the C/C cohort
(p < 0.001; Figure 3A). Moreover, serum SP-D levels of
patients with IIPs tended to be higher in the rs721917
T/T and be lower in the C/C cohort in both German
and Japanese populations (Figure 3A). Similarly, serum
SP-D levels also showed a trend to be different between
the genotypes of rs1998374 (Figure 3B) and rs2243639
(Figure 3C). In contrast, serum SP-D levels did not dif-
fer according to the rs3088308 genotypes (Figure 3D).
Correlation between serum SP-D levels and SFTPD gene
polymorphisms is statistically independent
Linear regression analyses were performed to further
examine whether the SFTD gene polymorphisms affect
serum SP-D levels independently from other covariates.
Univariate analyses revealed that the rs721917, rs1998374,
and rs2243639 genotypes correlated significantly with
serum SP-D levels (p < 0.001, p < 0.001, and p = 0.011, re-
spectively), but not that of rs3088308 (Table 3). We next
performed multivariate analysis, including age, ethnicity,
and case-control status (patients with IIPs vs HS) as
covariates, because these covariates showed significanthisms in SFTPD gene – patients with IIPs vs HS –
Japanese
HWE Total C/C T/C T/T HWE
0.862 63 19 30 14 0.973
(30.2%) (47.6%) (22.2%)
0.266 275 95 136 44 0.960
(34.5%) (49.5%) (16.0%)
p = 0.476
HWE Total C/C T/C T/T HWE
0.655 63 6 35 22 0.561
(9.5%) (55.6%) (34.9%)
0.913 275 57 125 93 0.679
(20.7%) (45.5%) (33.8%)
p = 0.102
HWE Total C/C T/C T/T HWE
0.960 63 28 28 7 1.000
(44.4%) (44.4%) (11.1%)
0.741 275 140 113 22 0.996
(50.9%) (41.1%) (8.0%)
p = 0.563
HWE Total A/A A/T T/T HWE
0.711 63 59 4 0 0.968
(93.7%) (6.3%) (0.0%)
0.913 275 265 10 0 0.955
(96.4%) (3.6%) (0.0%)
p = 0.330
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Figure 3 Relationship between genotype and serum SP-D levels. Serum SP-D levels were compared between each genotype: (A) rs721917,
(B) rs1998374, (C) rs2243639, and (D) rs3088308. For each genotype, data of the German cohort are shown in the left and those of the Japanese
cohort are shown in the right. The horizontal bars represent the mean values. (A), (B), (C) The significance level was defined as α = 0.006
(nine comparisons in six groups). ***p < 0.001, **p < 0.006 (Mann–Whitney U-test). (D) The significance level was defined as α = 0.0125
(four comparisons in four groups). ***p < 0.001, **p < 0.013 (Mann–Whitney U-test).
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lyses (p < 0.001, p < 0.001, and p < 0.001, respectively).
The rs721917, rs1998374, and rs2243639 genotypes sig-
nificantly correlated with serum SP-D levels in multi-
variate analyses (p < 0.001, p = 0.001, and p = 0.038,
respectively) as well. Further, among the three covari-
ates, only the case-control status revealed significant
correlations with serum SP-D levels in the three multivari-
ate models (p < 0.001, p < 0.001, p < 0.001, respectively;
Table 3), although age and ethnicity did not significantly
correlate with serum SP-D levels.
Discussion
In the present study, we demonstrated that serum SP-A
and SP-D levels were significantly higher in patients with
IIPs than in HS in both German and Japanese subjects.
Moreover, we found that in patients with IIPs and HS,serum SP-D levels were significantly higher in the
German than in the Japanese cohort, whereas there
were no significant differences in serum SP-A levels
between the two cohorts. The genotype distributions
of SNPs in the SFTPD gene, which affect the serum
SP-D levels, differed between the cohorts. Further-
more, multivariate analyses demonstrated that there
were statistically independent correlations between serum
SP-D levels and the rs721917, rs1998374, and rs2243639
genotypes of the SFTPD gene, regardless of ethnicity and
presence of IIPs.
The significantly higher serum SP-A and SP-D levels in
patients with IIPs compared with those of the German HS
suggest their utility as diagnostic biomarkers for IIPs, even
in the German population. Serum SP-A levels in the
German patients with IIPs or HS were comparable to
those in their Japanese counterparts (Figure 2A); however,
Table 3 Correlations between serum SP-D levels and SFTPD gene polymorphisms
Variable Regression coefficient (95% CI.) p value VIF
rs721917 Univariate model
C/C vs T/C vs T/T 55.276 (28.473 – 82.079) < 0.001
Multivariate model
C/C vs T/C vs T/T 35.149 (15.341 – 54.957) < 0.001 1.031
Age −0.444 (−2.009 – 1.121) 0.578 1.978
Japanese vs German 24.061 (−13.125 – 61.246) 0.204 1.437
HS vs patients with IIPs 307.740 (260.743 – 354.736) < 0.001 2.515
rs1998374 Univariate model
C/C vs T/C vs T/T 86.550 (59.832 – 113.269) < 0.001
Multivariate model
C/C vs T/C vs T/T 36.172 (14.289 – 58.056) 0.001 1.203
Age −0.353 (−1.918 – 1.213) 0.658 1.972
Japanese vs German 11.114 (−28.165 – 50.393) 0.578 1.598
HS vs patients with IIPs 304.645 (257.602 – 351.689) < 0.001 2.511
rs2243639 Univariate model
C/C vs T/C vs T/T 38.179 (8.965 – 67.393) 0.011
Multivariate model
C/C vs T/C vs T/T 22.707 (1.310 – 44.104) 0.038 1.017
Age −0.360 (−0.449 – 0.654) 0.654 1.976
Japanese vs German 29.314 (−8.000 – 66.627) 0.123 1.423
HS vs patients with IIPs 306.421 (259.045 – 353.798) < 0.001 2.514
rs3088308 Univariate model
A/A vs A/T 37.750 (−37.732 – 113.231) 0.326
The genotypes of each single nucleotide polymorphism are arranged in the order of lowest to highest serum SP-D levels.
CI, Confidence interval; HS, Healthy subjects; IIPs, Idiopathic interstitial pneumonias; VIF, Variance inflation factor.
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were significantly higher than those in their Japanese
counterparts (Figure 2B). These results imply that serum
SP-D levels are affected by the different ethnicity, whereas
serum SP-A levels are not. In agreement with our present
study results, serum SP-D levels in Caucasian HS were re-
ported to be higher than those in Asian HS [32].
To explain the differences in serum SP-D levels be-
tween the German and Japanese cohorts, we determined
the relationship between serum SP-D levels and geno-
typic differences in the SFTPD gene. We found that
among the SNPs in SFTPD gene, rs721917, rs1998374,
and rs2243639, but not rs3088308, affected the serum
SP-D levels (Figure 3), and the distributions of these
polymorphisms were different between the German and
Japanese cohorts. SP-A and SP-D molecules comprise an
N-terminal domain (NTD), a collagen domain, an α-
helical neck region, and a carbohydrate recognition
domain (CRD; Figure 1) [33]. SP-D polypeptide chains
bind together through interpolypeptide disulfide bonds in
the NTD to form oligomers, and the degree of oligo-
merization is affected by the genotypes of coding SNP
rs721917 in the NTD. Thus, the T/T and C/C genotypescorrelate with higher and lower-order oligomers, respect-
ively [33-36]. These structural variations of SP-Ds might
affect their serum levels, and our results demonstrate that
serum SP-D levels differed according to the rs721917
genotype (Figure 3A). Furthermore, we also found that
serum SP-D levels were affected by the genotypes of
rs1998374 and rs2243639, both of which are located in
the collagen domain (Figures 1, 3B and C), but they were
not affected by the genotypes of rs3088308, the coding
SNP in the CRD (Figures 1 and 3D). These findings
suggest the possibility that the collagen domain is
also associated with the degree of oligomerization of
the SP-D molecule.
To determine whether serum SP-D levels were inde-
pendently correlated with SFTPD gene polymorphisms
and/or ethnicity, we performed multivariate regression
analyses and found that the correlations between the ge-
notypes of three SNPs in the SFTPD gene and serum
SP-D levels remained statistically significant in the mul-
tivariate models (Table 3). In contrast, the correlations
between ethnicity and serum SP-D levels were insigni-
ficant (Table 3). These findings suggest that serum
SP-D levels are more strongly affected by SFTPD gene
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rence in serum SP-D levels that were observed between
German and Japanese cohorts might be partially explained
by the differences in the frequencies of SFTPD gene poly-
morphisms between the cohorts.
In contrast, we found that the genotype distributions
of four SNPs in the SFTPD gene did not differ between
patients with IIPs and HS in both cohorts (Table 2).
SP-A and SP-D play important roles in surfactant-related
functions and in host defense against inhaled pathogens
[37]. Moreover, SFTPD gene polymorphisms, rs721917
in particular, have been reported to correlate with sus-
ceptibility to COPD, community-acquired pneumonia,
ILDs, and lung cancer [23,38-41]. As discussed above,
rs721917 is known to be associated with the degree
of oligomerization of the SP-D molecules [33-36]. This
difference in oligomerization might affect the surfac-
tant and/or host defense functions of SP-D and thus
correlate with susceptibility to various respiratory di-
seases. In the present study, however, no significant
correlation between SFTPD gene polymorphisms and
susceptibility to IIPs was demonstrated. We believe that a
larger sample size of study is needed to determine the cor-
relations between SFTPD gene polymorphisms and sus-
ceptibility to IIPs.
We are aware that there are some limitations in this
study. First, age, gender, and smoking status were signifi-
cantly different between German HS and Japanese HS
because the populations who undergo health checkup
were different between Germany and Japan. We per-
formed linear regression analysis to assess the inter-
ference between these factors and serum SP-D levels,
and we found a significant correlation between age and
serum SP-D levels. Thus, we included age into the
multivariate analyses and confirmed that our results
were significant and independent of age differences. Se-
cond, the number of subjects available for genomic ana-
lyses was relatively small. Third, only German and
Japanese populations were studied. It remains unclear
whether the findings of the present study can be applied
to other ethnic groups such as African Americans.
Conclusions
In conclusion, we demonstrated that the serum levels of
SP-A and SP-D were significantly elevated in patients
with IIPs in the German and Japanese cohorts, whereas
serum SP-D but not SP-A levels were significantly higher
in the German cohort. We have explained the differences
in serum SP-D levels between these cohorts, at least in
part, by the different frequencies of SFTPD gene polymor-
phisms. Although we believe that these data are compel-
ling, further investigations with larger number of subjects
are required to assess the utility of serum SP-A and SP-D
in non-Japanese cohorts.Additional files
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